Kyverna therapeutics announces new patient data highlighting potential of kyv-101 for treatment of lupus nephritis in symposium at acr convergence 2024

Positive sustained efficacy and durability at >6-month follow-up observed in patients with severe lupus nephritis (ln) treated with kyv-101 target dose kyv-101 treatment continues to demonstrate robust safety and tolerability with no high-grade crs or icans observed emeryville, calif. , nov. 14, 2024 /prnewswire/ -- kyverna therapeutics, inc. (kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announces today that it will present updated clinical data from ln patients treated with kyv-101 in ongoing kyverna-sponsored kysa-1 and kysa-3 phase 1/2 studies and named patient treatments.
KYTX Ratings Summary
KYTX Quant Ranking